Search research articles
Contact Us
Filters
Showing results (21-30 of 34) with videos related to
Page
of 4
Sort By:
Translational Oncology
|
January 5, 2025
TNG908 is a brain-penetrant, MTA-cooperative PRMT5 inhibitor developed for the treatment of MTAP-deleted cancers
Kimberly J Briggs, Kevin M Cottrell, Matthew R Tonini, et al.
Biomaterials
|
October 2, 2024
Engineered 3D human neurovascular model of Alzheimer's disease to study vascular dysfunction
Georgios Pavlou, Sarah Spitz, Francesca Michela Pramotton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 24, 2025
MTA-Cooperative PRMT5 Inhibitors are Efficacious in MTAP-Deleted Malignant Peripheral Nerve Sheath Tumor Models
Xiaochun Zhang, Dana C Borcherding, Minjie Zhang, et al.
Clinical Pharmacology and Therapeutics
|
December 3, 2020
Physiologically-Based Pharmacokinetic Modeling in Renal and Hepatic Impairment Populations: A Pharmaceutical Industry Perspective
Tycho Heimbach, Yuan Chen, Jun Chen, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
January 20, 2018
Preclinical QSP Modeling in the Pharmaceutical Industry: An IQ Consortium Survey Examining the Current Landscape
Marjoleen J M A Nijsen, Fan Wu, Loveleena Bansal, et al.
Journal of Medicinal Chemistry
|
April 10, 2024
Discovery of TNG908: A Selective, Brain Penetrant, MTA-Cooperative PRMT5 Inhibitor That Is Synthetically Lethal with <i>MTAP</i>-Deleted Cancers
Kevin M Cottrell, Kimberly J Briggs, Douglas A Whittington, et al.
Drug Discovery Today
|
May 7, 2017
Translational pharmacokinetic-pharmacodynamic analysis in the pharmaceutical industry: an IQ Consortium PK-PD Discussion Group perspective
Harvey Wong, Tonika Bohnert, Valeriu Damian-Iordache, et al.
Bioorganic & Medicinal Chemistry Letters
|
May 2, 2025
Discovery of TNG-6132, a potent, selective, and orally bioavailable USP1 inhibitor
Scott Throner, Tianshu Feng, Jannik N Andersen, et al.
ACS Medicinal Chemistry Letters
|
February 16, 2017
Novel 2-Substituted 7-Azaindole and 7-Azaindazole Analogues as Potential Antiviral Agents for the Treatment of Influenza
Upul K Bandarage, Michael P Clark, Emanuele Perola, et al.
The AAPS Journal
|
January 30, 2015
Preclinical pharmacokinetic/pharmacodynamic modeling and simulation in the pharmaceutical industry: an IQ consortium survey examining the current landscape
Edgar Schuck, Tonika Bohnert, Arijit Chakravarty, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 34) with videos related to
Sort By:
Page
of 4
Translational Oncology
|
January 5, 2025
TNG908 is a brain-penetrant, MTA-cooperative PRMT5 inhibitor developed for the treatment of MTAP-deleted cancers
Kimberly J Briggs, Kevin M Cottrell, Matthew R Tonini, et al.
Biomaterials
|
October 2, 2024
Engineered 3D human neurovascular model of Alzheimer's disease to study vascular dysfunction
Georgios Pavlou, Sarah Spitz, Francesca Michela Pramotton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 24, 2025
MTA-Cooperative PRMT5 Inhibitors are Efficacious in MTAP-Deleted Malignant Peripheral Nerve Sheath Tumor Models
Xiaochun Zhang, Dana C Borcherding, Minjie Zhang, et al.
Clinical Pharmacology and Therapeutics
|
December 3, 2020
Physiologically-Based Pharmacokinetic Modeling in Renal and Hepatic Impairment Populations: A Pharmaceutical Industry Perspective
Tycho Heimbach, Yuan Chen, Jun Chen, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
January 20, 2018
Preclinical QSP Modeling in the Pharmaceutical Industry: An IQ Consortium Survey Examining the Current Landscape
Marjoleen J M A Nijsen, Fan Wu, Loveleena Bansal, et al.
Journal of Medicinal Chemistry
|
April 10, 2024
Discovery of TNG908: A Selective, Brain Penetrant, MTA-Cooperative PRMT5 Inhibitor That Is Synthetically Lethal with <i>MTAP</i>-Deleted Cancers
Kevin M Cottrell, Kimberly J Briggs, Douglas A Whittington, et al.
Drug Discovery Today
|
May 7, 2017
Translational pharmacokinetic-pharmacodynamic analysis in the pharmaceutical industry: an IQ Consortium PK-PD Discussion Group perspective
Harvey Wong, Tonika Bohnert, Valeriu Damian-Iordache, et al.
Bioorganic & Medicinal Chemistry Letters
|
May 2, 2025
Discovery of TNG-6132, a potent, selective, and orally bioavailable USP1 inhibitor
Scott Throner, Tianshu Feng, Jannik N Andersen, et al.
ACS Medicinal Chemistry Letters
|
February 16, 2017
Novel 2-Substituted 7-Azaindole and 7-Azaindazole Analogues as Potential Antiviral Agents for the Treatment of Influenza
Upul K Bandarage, Michael P Clark, Emanuele Perola, et al.
The AAPS Journal
|
January 30, 2015
Preclinical pharmacokinetic/pharmacodynamic modeling and simulation in the pharmaceutical industry: an IQ consortium survey examining the current landscape
Edgar Schuck, Tonika Bohnert, Arijit Chakravarty, et al.
Page
of 4